Straits Times Index
3,330.77 -0.04 (-0.00%) Nikkei
38,683.93 -19.58 (-0.05%) Hang Seng
18,366.95 -109.85 (-0.59%) FTSE 100
8,245.37 -39.97 (-0.48%) Bitcoin USD
68,507.26 -2,388.90 (-3.37%) CMC Crypto 200
1,453.04 -25.66 (-1.73%)
MRK Jan 2025 85.000 call
| Previous close | 41.60 |
| Open | 41.60 |
| Bid | 46.10 |
| Ask | 47.40 |
| Strike | 85.00 |
| Expiry date | 2025-01-17 |
| Day's range | 41.60 - 41.60 |
| Contract range | N/A |
| Volume | |
| Open interest | 141 |
Insider MonkeyThe City With the highest HIV/AIDS Rates in the US
We recently compiled a list of 20 Cities With the Highest HIV/AIDS Rates in the US and in this article, we will talk about the city with the highest HIV/AIDS rates in the US. HIV Incidence and Prevalence in the United States The government of the United States has set a goal to reduce the […]
Business WireMerck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
RAHWAY, N.J., June 05, 2024--Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
BenzingaModerna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients
Monday, Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc (NYSE:MRK) announced the first presentation of results from a planned analysis from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study. The study is evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with Merck’s Keytruda in patients with resected high-risk melanoma (stage III/IV) following complete resection (n=157). With a median follow-up of approximately three years (34.9 months), adjuvant tr
